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Abstract
Background
Time from symptomatic presentation to cancer diagnosis (diagnostic interval) is an impor-
tant, and modifiable, part of the patient’s cancer pathway, and can be affected by various
factors such as age, gender and type of presenting symptoms. The aim of this study was to
quantify the relationships of diagnostic interval with these variables in 15 cancers diagnosed
between 2007 and 2010 using routinely collected data from the Clinical Practice Research
Datalink (CPRD) in the UK.
Methods
Symptom lists for each cancer were prepared from the literature and by consensus amongst
the clinician researchers, which were then categorised into either NICE qualifying (NICE) or
not (non-NICE) based on NICE Urgent Referral Guidelines for Suspected Cancer criteria.
Multivariable linear regression models were fitted to examine the relationship between diag-
nostic interval (outcome) and the predictors: age, gender and symptom type.
Results
18,618 newly diagnosed cancer patients aged40 who had a recorded symptom in the pre-
ceding year were included in the analysis. Mean diagnostic interval was greater for older pa-
tients in four disease sites (difference in days per 10 year increase in age; 95% CI): bladder
(10.3; 5.5 to 15.1; P<0.001), kidney (11.0; 3.4 to 18.6; P=0.004), leukaemia (18.5; 8.8 to
28.1; P<0.001) and lung (10.1; 6.7 to 13.4; P<0.001). There was also evidence of longer di-
agnostic interval in older patients with colorectal cancer (P<0.001). However, we found that
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mean diagnostic interval was shorter with increasing age in two cancers: gastric (-5.9; -11.7
to -0.2; P=0.04) and pancreatic (-6.0; -11.2 to -0.7; P=0.03). Diagnostic interval was longer
for females in six of the gender non-specific cancers (mean difference in days; 95% CI):
bladder (12.2; 0.8 to 23.6; P=0.04), colorectal (10.4; 4.3 to 16.5; P=0.001), gastric (14.3; 1.1
to 27.6; P=0.03), head and neck (31.3; 6.2 to 56.5; P=0.02), lung (8.0; 1.2 to 14.9; P=0.02),
and lymphoma (19.2; 3.8 to 34.7; P=0.01). Evidence of longer diagnostic interval was found
for patients presenting with non-NICE symptoms in 10 of 15 cancers (mean difference in
days; 95% CI): bladder (62.9; 48.7 to 77.2; P<0.001), breast (115.1; 105.9 to 124.3;
P<0.001), cervical (60.3; 31.6 to 89.0; P<0.001), colorectal (25.8; 19.6 to 31.9; P<0.001),
gastric (24.1; 3.4 to 44.8; P=0.02), kidney (22.1; 4.5 to 39.7; P=0.01), oesophageal (67.0;
42.1 to 92.0; P<0.001), pancreatic (48.6; 28.1 to 69.1; P<0.001), testicular (36.7; 17.0 to
56.4; P< 0.001), and endometrial (73.8; 60.3 to 87.3; P<0.001). Pooled analysis across all
cancers demonstrated highly significant evidence of differences overall showing longer di-
agnostic intervals with increasing age (7.8 days; 6.4 to 9.1; P<0.001); for females (8.9 days;
5.5 to 12.2; P<0.001); and in non-NICE symptoms (27.7 days; 23.9 to 31.5; P<0.001).
Conclusions
We found age and gender-specific inequalities in time to diagnosis for some but not all can-
cer sites studied. Whilst these need further explanation, these findings can inform the devel-
opment and evaluation of interventions intended to achieve timely diagnosis and improved
cancer outcomes, such as to provide equity across all age and gender groupings.
Introduction
Rapid diagnosis of cancer after symptoms arise is believed to be important to improve out-
comes [1], and patient and/or their carer experience [2, 3]. It is thought that thousands of
deaths may be avoided annually if cancers are diagnosed quickly and successfully treated [4–7].
Hence, prompt diagnosis of symptomatic patients has become a priority worldwide [1, 7–9].
The National Awareness and Early Diagnosis Initiative (NAEDI) in England [10] and similar
initiatives elsewhere in Europe [9] are trying to address this.
Most patients with cancer-related symptoms present to a primary health care practitioner,
usually a GP, who then has to suspect a cancer, or other illness, and initiate an investigation or
referral for diagnosis. This period between the first primary care presentation of potential can-
cer symptoms and eventual diagnosis, the ‘diagnostic interval’ [11, 12] is one of the important
phases in the route to diagnosis of many cancers [11, 13]. Shorter diagnostic interval is general-
ly considered to contribute to overall earlier stage diagnoses and better cancer outcomes [5, 6].
Suspecting a cancer diagnosis in primary care may be difficult, as many of the symptoms of
cancer can arise from co-morbidities or benign causes [14]. Hence, there is both a potential for
delay at this point [12, 13], as well as an opportunity to detect a cancer earlier [15], as an esti-
mated one in 20 consultations in primary care include possible malignant symptomatology
[16]. The speed of cancer diagnosis may vary by demographic characteristics, such as age and
gender, [17, 18] making some groups vulnerable and disadvantaged in both being diagnosed
and treated late, [19–21], leading to poorer survival [22].
Primary care datasets are a key resource for studying cancer diagnostic pathways and have
previously been used to determine the positive predictive value of cancer symptoms [23, 24];
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the change in diagnostic interval over time for various cancers [12]; and to construct clinical
decision support tools [25, 26]. These datasets can also be used to examine the association be-
tween the time to diagnosis and demographic variables for specific cancer symptoms presented
to primary care.
The aim of this study was to quantify differences in cancer diagnostic intervals across sub-
groups defined by age, gender and symptom type in 15 types of incident cancer diagnosed be-
tween 2007 and 2010 in England and Wales, UK using routinely collected primary care data.
This could facilitate an understanding of variation in diagnostic interval and inform the devel-
opment and evaluation of targeted interventions to facilitate timelier diagnosis.
Methods
This analysis was undertaken alongside a previously reported study [12], extending the scope
to examining the relationship of diagnostic interval with age, gender and symptom type. A
more detailed description of applying cancer (S1 Table) and symptom (S2 and S3 Tables)
codes to the dataset, and the process of identification and validation of these codes is given in
that report and has been supplied as supplementary files for readers’ reference for this report.
Ethical approval for this study was obtained from the Independent Scientific Advisory
Committee (ISAC), under license numbers 09_0110 and 09_0111. All patient records/informa-
tion was anonymised and de-identified when the dataset was obtained from the Clinical Prac-
tice Research Datalink—CPRD (General Practice Research Database-GPRD, at the time the
data was acquired) and the analysis did not comprise any patient identifiable data.
Source population dataset
We used routinely collected UK general practice data obtained from the CPRD for 15 types of
incident cancer (bladder, breast, cervical, colorectal, endometrial, gastric, head & neck, kidney,
lung, leukaemia, lymphoma, myeloma, oesophageal, pancreatic, testicular) with at least one
year of complete records before diagnosis. The CPRD is a large, longitudinal general practice
database holding anonymised records of over five million active patients registered with over
650 general practices in England and Wales in the UK. General practices that agree to and fulfil
strict quality criteria for data entry and maintenance only can contribute to this database and
the data is then periodically quality checked to ascertain and maintain its robustness. At the
practice level, the GP enters the most appropriate terms related to symptoms or diagnosis
based on a list of drop down choices corresponding to the appropriate Oxford Medical Infor-
mation Systems (OXMIS) and Read codes [27].
The dataset used in this study consisted of patients aged40 years diagnosed between 1st
Jan 2007 and 31st Dec 2010 inclusive with one of 15 cancers of interest described earlier.
NICE cancer symptom categories (NICE status)
Lists of potential symptoms (S4 Table) of primary, local and regional disease for the cancers of
interest for this study were developed from the literature, and by consensus, amongst the three
clinician researchers (RN, WH, GR), and were classified into ‘NICE-qualifying symptoms’
(NICE) or not (non-NICE) [12] (S5 Table). These symptom categories are sometimes referred
to as ‘alarm symptoms’ and ‘vague symptoms’ respectively in the literature [23]. NICE symp-
toms were those specifically cited in the NICE Guideline for Urgent Referral of Suspected Can-
cer [28] as mandating urgent investigation or specialist assessment.
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Diagnostic interval
The first occurrence of a cancer code in patient’s primary care record in the CPRD dataset (S1
Table) pertaining to the cancer diagnosis was assigned to be the date of diagnosis [12, 25] and
the clinical record for the 12 month period preceding this date was studied. The ‘diagnostic in-
terval’ was defined as the duration from the first occurrence of a symptom code in CPRD per-
taining to a possible cancer to the date of cancer diagnosis, and was censored at 365 days.
Hence, the diagnostic interval was calculated only for patients with identifiable symptom
codes. The patients who were screen- or incidentally-detected, or who had emergency admis-
sions without any symptom information were excluded. Although there have been reports of
patients experiencing symptoms for more than a year before diagnosis [29], it is difficult to
know whether very early symptoms genuinely arise from the cancer in question, or from be-
nign or incidental conditions. We chose 365 days as a reasonable compromise in the absence of
any methodological precedence [12] and it is in keeping with recently published consensus rec-
ommendations [13].
Data analysis
We examined the relationships between diagnostic interval and each of age, gender and NICE
status. Separate analyses were carried out for each cancer site as well as a single overall analysis
that included all cancers.
Numbers and percentages of symptomatic patients in the dataset, males and females, and
patients with either NICE or non-NICE symptoms [12] among the symptomatic patients for
each cancer site are reported. The mean age at diagnosis is reported for each cancer site. The
distribution of diagnostic interval was summarised, reporting the mean, standard deviation,
median, inter-quartile range (IQR), and 90th centile. Median, IQR and 90th centiles are shown
as the preferred method for describing these skewed data, but comparisons across sub-groups
are based on mean diagnostic interval (using linear regression models with diagnostic interval
as the outcome and age, gender, and NICE status as predictors) as this was the parameter we
wanted to make inferences for. Because the diagnostic interval distributions were skewed, we
validated the linear regression results by constructing bias-corrected accelerated bootstrap con-
fidence intervals for the mean differences (regression coefficients) as these are robust to non-
normality [30]. As the bootstrap confidence intervals were virtually the same as the regression
model-based confidence intervals we report results from the latter analysis. The four gender-
specific cancers (breast, cervical, endometrial and testicular) were omitted from the analyses of
diagnostic intervals against gender.
Unadjusted (crude) linear regression models were fitted in which only one predictor was in-
cluded and multivariable models in which all three of age, gender, and NICE status were in-
cluded as predictors. We focus on the multivariable analyses as primary. Fractional polynomial
models were used to check that the continuous predictor, age, had a linear relationship with di-
agnostic interval. Where the relationship was linear we reported the increase in mean diagnos-
tic interval for every 10 year increase in age. Where the relationship was non-linear we divided
the patient sample into five equal sized age categories based on the quintiles and used age as a
categorical predictor in the linear regression model, comparing the mean of each of the four
older categories to the youngest age category (reference category).
Where there was evidence at the 5% level of an association between diagnostic interval and
the age and gender predictors, tests of interaction were undertaken to explore whether the rela-
tionships differ between categories defined by NICE status. All data manipulation and analyses
were performed using Stata 11.0 software (StataCorp. 2009. Stata Statistical Software: Release
11. College Station, TX: StataCorp LP.).
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Results
Demographic and symptom profile of the study sample
33,008 patients had a new diagnosis of cancer during the study period; of these 18,618 (56.4%)
had a recorded symptom in the 12 months before diagnosis, so were included in the analyses.
Mean age varied among cancers ranging from 50.8 (SD 10.5) years for testicular to 73.5 (SD
10.4) years for bladder. Because the dataset only contained patients aged 40 years or more, the
mean ages for those cancers also affecting younger people are artefactually high. Percentages of
patients with symptoms varied among cancer sites with leukaemia having the lowest (19.5%)
and oesophageal having the highest (75.4%) percentage of symptomatic patients respectively.
Patients presenting with NICE symptoms were considerably more common than with non-
NICE symptoms for all cancers except cervical. More males than females had symptoms for all
the gender non-specific cancers except lymphoma (49.9%) and pancreatic (46.6%). The general
characteristics of patients with no symptoms were similar to the symptomatic population in all
cancers, though these data are not presented here as the focus of this study was symptomatic
cancer patients. Table 1 summarises the patient demographic characteristics regarding age,
gender and percentage of symptomatic patients in each cancer group in the dataset.
Diagnostic interval distributions
Mean (SD) diagnostic intervals were shortest for testicular cancer (54.5 days (50.8)) and longest
for myeloma (161.8 days (114.0)). The cancers with the shortest median diagnostic intervals
(Table 2) were breast (27 days), testicular (41 days), and pancreatic (59 days); and those with
the longest were myeloma (149 days), lung (113 days), and leukaemia (102 days). Similarly, the
cancers with the shortest 90th centile diagnostic intervals were testicular (113 days), breast (210
Table 1. Demographic characteristics of the patient population in the dataset.
Cancer site Number diagnosed (n) n (%)* with symptoms n (%)** with NICE symptoms Age at diagnosis n (%)*** females
Median Mean SD
Bladder 2210 1519 (68.7) 1299 (85.5) 74 73.5 10.4 395 (26.0)
Breast 3147 1620 (51.5) 1316 (81.2) 66 67.1 13.3 1620 (100)
Cervix 421 150 (35.6) 68 (45.3) 57 59.4 14.9 150 (100)
Colorectal 6557 4363 (66.5) 2508 (57.5) 73 72 11.2 1984 (45.6)
Gastric 2021 1118 (55.3) 1002 (89.6) 74 72.9 10.8 397 (35.5)
Head and Neck 612 328 (53.6) 282 (86.0) 69 67.9 12.3 68 (20.7)
Kidney 1467 503 (34.3) 272 (54.0) 70 68.7 11.4 172 (34.2)
Leukaemia 1961 383 (19.5) 370 (96.6) 72 70.7 11.9 185 (48.3)
Lung 6552 4253 (64.9) 3816 (89.7) 73 72.1 10.3 1821 (42.8)
Lymphoma 2232 685 (30.7) 652 (95.2) 70 68.8 12 343 (50.1)
Myeloma 1158 500 (43.2) 497 (99.4) 72 71.4 10.8 218 (43.6)
Oesophageal 1842 1389 (75.4) 1314 (94.6) 72 71.0 11.1 464 (33.4)
Pancreatic 1370 946 (69.1) 859 (90.8) 73 71.9 11.7 505 (53.4)
Testicular 161 104 (64.6) 68 (65.4) 47 50.8 10.5 104 (100)
Endometrial 1297 757 (58.3) 571 (75.4) 66 66.9 10.9 757 (100)
Pooled 33008 18618 (56.4) 14894 (80.0) 72 70.6 11.7 6552 (41.0)
* Number of with symptoms as a fraction of the number with cancer diagnosis
**Number with NICE symptoms as a fraction of the number with symptoms (fraction of those analysed)
*** Number of females as a fraction of the number with symptoms (fraction of those analysed).
doi:10.1371/journal.pone.0127717.t001
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days), and cervical (228 days); and those with the longest were myeloma (334 days), lung (326
days), leukaemia (311 days) and gastric (310 days).
Diagnostic intervals and age
The results from fitted fractional polynomial linear regression models indicated that the rela-
tionship between age and diagnostic interval was linear for all cancers except colorectal (Fig 1),
in which the age was hence analysed as a categorical predictor in the linear regression model.
The adjusted mean change in diagnostic interval per 10 year increase in age ranged from a
19 day increase for leukaemia to a 6 day decrease for pancreatic and gastric cancers (Table 2).
There was evidence of a relationship between diagnostic interval and age for seven of the can-
cers in the multivariable analysis showing longer diagnostic interval with increasing age for five
cancers (mean change per 10 year increase in age; 95% confidence interval; p value): bladder
(10.3 days; 95% CI: 5.5 to 15.1; P<0.001), kidney (11.0 days; 95% CI: 3.4 to 18.6; P = 0.004),
leukaemia (18.5 days; 95% CI: 8.8 to 28.1; P<0.001), lung (10.1 days; 95% CI: 6.7 to 13.4;
P<0.001) and colorectal (P<0.001—see Table 3); whereas mean diagnostic interval was
shorter for two of the cancers: gastric (-5.9 days; 95% CI: -11.7 to -0.2; P = 0.04) and pancreatic
(-6.0 days; 95% CI: -11.2 to -0.7; P = 0.03). There were no significant differences in other can-
cers. Pooling the patients from all cancers (Table 2) resulted in strong evidence of a relationship
showing longer diagnostic interval with increasing age (7.8 days per 10 year increase; 6.4 to 9.1;
P<0.001). No evidence at the 5% level of significance was found of an interaction between age
and NICE status for any cancer type.
Table 2. Regression analysis of diagnostic intervals against age* in 15 cancers.
Cancer site n Diagnostic interval
Mean SD Median Interquartile range 90th centile Incremental change in days per 10 years of age
Mean (95% CI) Adjusted* P value
Crude Adjusted*
Bladder 1519 119.0 102.6 80 40 to 179 293 12.0 10.3 (5.5 to 15.1) <0.001
Breast 1620 63.3 86.3 27 15 to 62 210 0.1 -1.3 (-3.8 to 1.2) 0.30
Cervix 150 98.8 89.6 67 30 to 145 228 -1.6 3.7 (-5.9 to 13.4) 0.44
Colorectal 4363 120.3 103.3 80 37 to 188 296 NA** NA** NA**
Gastric 1118 125.0 107.8 84 35 to 199 310 -5.0 -5.9 (-11.7 to -0.2) 0.04
Head and Neck 328 121.3 94.4 87 51 to 177 281 -2.9 -3.3 (-11.8 to 5.1) 0.43
Kidney 503 119.0 99.8 84 42 to 175 293 12.5 11.0 (3.4 to 18.6) 0.004
Leukaemia 383 133.5 113.9 102 28 to 230 311 17.8 18.5 (8.8 to 28.1) <0.001
Lung 4253 147.4 113.5 113 45 to 249 326 10.2 10.1 (6.7 to 13.4) <0.001
Lymphoma 685 130.0 103.3 99 44 to 209 298 2.5 2.8 (-3.5 to 9.0) 0.39
Myeloma 500 161.8 114.0 149 54 to 263 334 5.8 5.6 (-3.3 to 14.6) 0.21
Oesophageal 1389 125.6 108.2 83 35 to 207 308 -2.5 -3.0 (-8.1 to 2.1) 0.26
Pancreatic 946 96.5 93.5 59 26 to 145 248 -5.2 -6.0 (-11.2 to -0.7) 0.03
Testicular 104 54.5 50.8 41 20 to 66 113 4.5 2.7 (-6.2 to 11.5) 0.55
Endometrial 757 100.0 86.5 67 36 to 138 239 -2.4 0.4 (-5.4 to 6.1) 0.90
Pooled^ 18618 121.2 106.6 79 35 to 195 302 7.9 7.8 (6.4 to 9.1) <0.001
*Model adjusted for gender (where relevant) and NICE status
**Table 2b for analysis for colorectal site using age as a categorical predictor
^15987 for gender analysis in Table 3.
doi:10.1371/journal.pone.0127717.t002
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Diagnostic intervals and gender
The 11 gender non-specific cancers included 15,987 symptomatic patients (Table 4). There was
evidence at the 5% level of significance of gender differences for six cancers, all showing longer
diagnostic intervals for females: bladder (mean difference = 12.2 days; 0.8 to 23.6; P = 0.04), co-
lorectal (10.4 days; 4.3 to 16.5; P = 0.001), gastric (14.3 days; 1.1 to 27.6; P = 0.03), head and
neck (31.3 days; 6.2 to 56.5; P = 0.02), lung (8.0 days; 1.2 to 14.9; P = 0.02), and lymphoma
(19.2 days; 3.8 to 34.7; P = 0.01). Pooling (Table 4) the patients from all cancers resulted in a
gender difference overall, with longer mean diagnostic interval for females (8.9 days; 5.5 to
Fig 1. Line graphs to illustrate fitted relationships between diagnostic interval and age.
doi:10.1371/journal.pone.0127717.g001
Table 3. Differences in diagnostic intervals across age categories* in colorectal cancer patients.
Age group categories Diagnostic interval
Mean (SD) Mean difference (95% CI) from youngest
age category *
Adjusted** P value
Crude Adjusted**
40 to 62 (youngest) 105.4 (95.3) Reference Reference <0.001
63 to 70 109.3 (98.3) 3.8 4.3 (-5.3 to 13.9)
71 to 76 118.4 (103.2) 13.0 14.0 (4.5 to 23.5)
77 to 81 125.7 (104.6) 20.0 21.4 (11.9 to 31.0)
82+ (oldest) 142.6 (103.3) 37.0 37.0 (27.4 to 46.6)
*Youngest age category (40–62) was used as the reference for comparison
**Model adjusted for gender and NICE status.
doi:10.1371/journal.pone.0127717.t003
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12.2; P<0.001). No evidence at the 5% level of significance was found of an interaction between
gender and NICE status for any cancer type.
Diagnostic intervals and NICE status
All 15 cancers were included in these analyses (Table 5). There was evidence that the diagnostic
interval was longer for non-NICE symptoms in 10 of the 15 cancers: bladder (mean differ-
ence = 62.9; 48.7 to 77.2; P<0.001), breast (115.1; 105.9 to 124.3; P<0.001), cervical (60.3; 31.6 to
89.0; P<0.001), colorectal (25.8; 19.6 to 31.9; P<0.001), gastric (24.1; 3.4 to 44.8; P = 0.02), kid-
ney (22.1; 4.5 to 39.7; P = 0.01), oesophageal (67.0; 42.1 to 92.0; P<0.001), pancreatic (48.6; 28.1
Table 4. Regression analysis of diagnostic interval by gender* in 11 gender non-specific cancers^.
Cancer site Gender n (%) Diagnostic interval
Mean SD Median Interquartile
range
90th
centile
Mean difference (95% CI) Adjusted* P
value
Crude Adjusted*
Bladder Males 1124
(74.0)
115.3 99.9 78 40 to 173 286 14.3 12.2 (0.8 to 23.6) 0.04
Females 395 (26.0) 129.6 109.4 88 43 to 196 312
Colorectal Males 2379
(54.5)
114.1 100.8 74 35 to 173 287 13.7 10.4 (4.3 to 16.5) 0.001
Females 1984
(45.6)
127.8 105.9 89 41 to 204 303
Gastric Males 721 (64.5) 119.9 106.0 77 35 to 182 306 14.3 14.3 (1.1 to 27.6) 0.03
Females 397 (35.5) 134.1 110.7 98 37 to 216 320
Head and
Neck
Males 260 (79.3) 114.5 91.2 84 48 to 158 270 33.2 31.3 (6.2 to 56.5) 0.02
Females 68 (20.7) 147.6 101.9 125 62 to 231 300
Kidney Males 331 (65.8) 113.8 98.2 78 38 to 162 284 15.2 8.1 (-10.4 to
26.6)
0.39
Females 172 (34.2) 129.0 102.4 101 44 to 196 300
Leukaemia Males 198 (51.7) 133.0 112.2 101 31 to 226 309 1.1 -1.1 (-23.7 to
21.5)
0.92
Females 185 (48.3) 134.1 115.9 104 27 to 237 312
Lung Males 2432
(57.2)
144.1 113.2 106 44 to 241 325 7.7 8.0 (1.2 to 14.9) 0.02
Females 1821
(42.8)
151.8 113.9 122 48 to 255 327
Lymphoma Males 342 (49.9) 120.1 96.7 86 40 to 183 269 19.7 19.2 (3.8 to 34.7) 0.01
Females 343 (50.1) 139.9 108.9 107 47 to 235 314
Myeloma Males 282 (56.4) 158.0 114.5 143 51 to 259 328 8.6 7.4 (-12.9 to
27.7)
0.47
Females 218 (43.6) 166.6 113.4 155 63 to 273 338
Oesophagus Males 925 (66.6) 123.7 107.4 80 35 to 197 308 5.5 6.2 (-5.9 to 18.3) 0.32
Females 464 (33.4) 129.3 109.6 90 35 to 221 307
Pancreatic Males 441 (46.6) 98.9 95.9 63 25 to 150 254 -4.4 -4.1 (-16.0 to 7.9) 0.50
Females 505 (53.4) 94.5 91.4 56 27 to 139 241
Pooled^ Males 9435
(59.0)
124.6 106.0 84 38 to 199 305 10.2 8.9 (5.5 to 12.2) <0.001
Females 6552
(41.0)
134.8 109.6 97 42 to 223 313
*Model adjusted for age and NICE status
**Number too small in NICE status to generate p value
^15987 for analysis of gender non-speciﬁc cancers.
doi:10.1371/journal.pone.0127717.t004
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to 69.1; P<0.001), testicular (36.7; 17.0 to 56.4; P< 0.001), and endometrial (73.8; 60.3 to 87.3;
P<0.001). Pooling (Table 5) the patients from all cancers resulted in strong evidence of an overall
increase in diagnostic interval for non-NICE symptoms (27.7 days; 23.9 to 31.5; P<0.001).
Discussion
Summary of the main findings
The overall findings were that longer diagnostic intervals are associated with increased age, fe-
male gender and non-NICE symptoms. Not all cancer sites had these associations: for older
Table 5. Regression analysis of diagnostic intervals byNICE status in 15 cancers.
Cancer site NICE
status
n (%) Diagnostic interval
Mean SD Median Interquartile
range
90th
centile
Mean difference (95% CI) P
value*
Crude Adjusted*
Bladder NICE 1299 (85.5) 109.5 99.0 71 37 to 155 284 62.9 62.9 (48.7 to 77.2) <0.001
non-NICE 220 (14.5) 175.0 105.9 172 87 to 268 327
Breast NICE 1316 (81.2) 41.8 59.7 22 14 to 42 83 114.9 115.1 (105.9 to
124.3)
<0.001
non-NICE 304 (18.8) 156.7 116.7 138 54 to 263 337
Cervical NICE 68 (45.3) 66.6 63.2 43 27 to 90 179 57.4 60.3 (31.6 to 89.0) <0.001
non-NICE 82 (54.7) 124.0 99.8 90 49 to 192 273
Colorectal NICE 2508 (57.5) 109.4 98.2 69 35 to 163 279 25.7 25.8 (19.6 to 31.9) <0.001
non-NICE 1855 (42.5) 135.1 108.2 100 43 to 218 310
Gastric NICE 1002 (89.6) 122.4 106.9 80 35 to 195 309 25.0 24.1 (3.4 to 44.8) 0.02
non-NICE 116 (10.4) 147.3 113.5 117 48 to 244 329
Head and
Neck
NICE 282 (86.0) 117.8 91.9 84 50 to 167 272 25.5 22.6 (-6.8 to 52.0) 0.13
non-NICE 46 (14.0) 143.3 106.8 101 55 to 218 312
Kidney NICE 272 (54.0) 106.9 94.0 76 39 to 145 281 26.2 22.1 (4.5 to 39.7) 0.01
non-NICE 231 (46.0) 133.2 104.7 104 44 to 211 296
Leukaemia NICE 370 (96.6) 134.4 114.3 103 28 to 231 312 -26.4 -39.5 (-102.2 to 23.1) 0.21
non-NICE 13 (3.4) 108.0 103.8 57 28 to 166 262
Lung NICE 3816 (89.7) 146.2 113.8 112 44 to 248 327 11.3 8.8 (-2.4 to 20.0) 0.12
non-NICE 437 (10.3) 157.5 110.5 139 60 to 257 323
Lymphoma NICE 652 (95.2) 131.1 102.9 100 46 to 210 295 -23.0 -22.8 (-58.4 to 14.0) 0.23
non-NICE 33 (4.8) 108.1 111.0 44 24 to 157 310
Myeloma NICE 497 (99.4) 162.2 113.9 149 54 to 263 334 -68.8 -65.8 (-195.8 to 64.2) 0.32
non-NICE 3 (0.6) 93.3 130.9 28 8 to 244 244
Oesophagus NICE 1314 (94.6) 121.9 106.5 79 34 to 200 300 67.2 67.0 (42.1 to 92.0) <0.001
non-NICE 75 (5.4) 189.1 117.0 169 89 to 306 352
Pancreatic NICE 859 (90.8) 92.3 91.4 56 25 to 131 242 67.2 48.6 (28.1 to 69.1) <0.001
non-NICE 87 (9.2) 138.6 104.0 115 43 to 211 293
Testicular NICE 68 (65.4) 41.5 32.5 35 20 to 57 77 37.4 36.7 (17.0 to 56.4) <0.001
non-NICE 36 (34.6) 78.9 68.0 56 29 to 110 182
Endometrial NICE 571 (75.4) 81.9 69.9 58 33 to 107 176 72.9 73.8 (60.3 to 87.3) <0.001
non-NICE 186 (24.6) 155.6 107.5 135 63 to 239 320
Pooled NICE 14894
(80.0)
115.7 105.1 73 32 to 183 296 27.5 27.7 (23.9 to 31.5) <0.001
non-NICE 3724 (20.0) 143.3 109.5 113 48 to 233 318
*Model adjusted for age and gender (where relevant).
doi:10.1371/journal.pone.0127717.t005
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age, longer diagnostic intervals were observed in five cancers (bladder, colorectal, kidney, leu-
kaemia and lung) but shorter diagnostic intervals in two cancers (gastric and pancreatic). Gen-
der analyses showed females had longer diagnostic interval than males, with significant
evidence at the 5% level in six cancers (bladder, colorectal, gastric, head and neck, lung, and
lymphoma). Presentation of a NICE symptom before diagnosis was associated with shorter di-
agnostic intervals in 10 of the 15 cancers (bladder, breast, cervical, colorectal, gastric, kidney,
oesophagus, pancreatic, testicular and endometrial). Data combined from all cancers included
in this study and analysed together showed that the diagnostic interval was longer for older pa-
tients, females and non-NICE symptoms.
Comparison with existing literature
This is the first study of this type to report the association between diagnostic interval and age
and gender for patients with cancer. There was evidence that diagnostic interval increased with
older age in five of 15 cancers. This finding is contradictory to a previous report [18] where lon-
ger diagnostic delays were reported for younger age groups, although this may be explained by
methodological differences such as: their data were collected from patient surveys, whereas
ours were GP-coded and collected from primary care consultations; they used different mea-
sures to analyse the data; there was a difference in the definition of diagnostic interval: number
of days from first symptomatic presentation to date of diagnosis was used in our study, whereas
‘primary care delay’ was used in their study (derived by subtracting referral delay from the du-
ration from noticing first symptoms to appointment by hospital doctor, based on patient recol-
lection of these events). The findings of our study align with those of a recent report of a
project piloted in five UK cancer network jurisdictions aimed, among others, at testing new
methods of clinical assessment of older cancer patients. One of the main findings was that
older cancer patients were being discriminated against, with care and treatment being deter-
mined based on age and not needs [21]. Other potential reasons to explain these findings in-
clude: changes in the nature, perception and presentation of symptoms with age [31], although
this has not been shown in previous studies [32]; increasing age-related co-morbidity with con-
current treatment(s) masking potential cancer symptoms [14, 31]; varying tumour biology and
aggressiveness with age [33] and/or gender [34]; a reluctance by GPs to refer or investigate
older and frailer people [35–37]; and differing age specific patterns in willingness to be referred
for onward investigation by the patients [38].
Longer diagnostic interval and advanced stage at diagnosis in females have been reported
before for some cancers [18, 19, 39] and our findings are in keeping with these; this is a useful
corroboration as our data source is different. The significant relationship of female gender with
longer diagnostic intervals in six of the 11 gender non-specific cancers analysed in our study
supports the findings of disparities reported in other studies that females might delay seeking
help when they detect or realise the presence of potential cancer related symptoms [14, 19] as
well as other chronic conditions such as heart disease [40], COPD [41] and others [42]. Al-
though, this trend appears to be improving [43], it still highlights the need for a deeper under-
standing of this multi-dimensional phenomenon [44] of gender difference to tailor
interventions according to patients’ socioeconomic and cultural background [45], especially
when females are reported to be keener on seeking more health related information [46], and
appear to be more receptive [47]. This finding also highlights the fact that symptoms should
not be overlooked by the health care professionals based on patients’ gender only.
This study adds to previous findings that ‘alarm’ symptoms that qualify a patient for urgent
referral (NICE) had shorter diagnostic interval than the ‘vague’ symptoms (non-NICE) [9, 12]
indicating that the symptoms that were already getting a good service are getting an even better
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one [31], and their prioritisation over more vague symptoms may lead to a ‘slow track’ for diag-
nosis [12, 48, 49].
Strengths and limitations
In the UK, over 95% of the population is uniquely registered with only one general practice.
Hence, the population data derived from the GP system is highly representative of the general
population. We used a large, longitudinal UK general practice dataset, which has previously
been used for cancer diagnostic studies [23, 24] and has been validated for diagnostic coding
accuracy of upto 95% in recent systematic reviews [27, 50].
Though our definition of diagnostic interval aligns with recent recommendations on the de-
sign and conduct of studies using such datasets [13], there are methodological weaknesses in
measuring diagnostic interval from electronic records [12]. This study used CPRD codes to ex-
tract symptom and cancer diagnosis dates from the dataset. The cancer diagnostic codes are
usually entered in the GP system by the practice staff upon receipt of the diagnostic confirma-
tion letter from a hospital bearing the date of diagnosis. There is a possibility at this stage that
the date of the letter itself or the date of coding entry might erroneously be entered as the date
of cancer diagnosis. This may affect the diagnostic interval in some cases. Likewise, some can-
cer diagnoses will have been unrecorded or recorded incorrectly, leading to either such cases
being excluded from our analysis or might have affected the correct diagnostic interval calcula-
tions respectively. These effects, though, are unlikely to affect a large proportion of the study
population when the CPRD databases have been validated to show a diagnostic coding accura-
cy of upto 95% recently [27, 50]. Similarly some symptoms might not have been recorded, or
recorded in a less accessible field (so-called ‘free-text’), although this may not be important be-
cause a recent CPRD study indicated that free-text data usually only confirms what is entered
in an accessible coded form [51], and electronic records have been found to be of similar quali-
ty to paper records [52]. Furthermore, some cancers might have presented with different or
atypical symptoms not included in our defined list. Also, we assumed that all the symptoms in
our list represented the symptomatic presentation of the cancer; however some may have been
co-incidental.
Although we were unable to specifically identify screen-detected patients, most would have
had no symptoms, and would therefore have been correctly excluded. Low proportions of
symptomatic patients in some cancers, such as breast, can be explained by the fact that between
39–46% patients can be screen-detected as reported in other UK studies using different data
sources [53, 54]; others could present with atypical symptoms or as emergency admissions.
The cut-off point for symptoms at 12 months prior to the date of diagnosis was based on
the judgement that very few would have had a diagnostic interval longer than this. If we had ex-
tended the time cut-off we would have picked more patients whose symptoms might not have
been related to subsequent cancer diagnosis, but we equally would have captured more patients
with genuine diagnostic interval of greater than one year. There may also be variation between
cancers; however, for consistency and in the absence of any methodological precedents, we
used the time period of 12 months for all the cancers as a compromise.
Patients under the age of 40 were not included. This was based on a practical decision be-
cause of the rarity of cancer diagnoses in this group; only 10% of all new cases in the UK occur
in the age group 25–49 [55]; and if they do occur, may be atypical or part of a familial syn-
drome [56, 57]. This approach is in keeping with similar primary care studies [12, 25]. Apart
from this, the age and symptom profile as well as male to female ratios in our datasets are simi-
lar to other national cancer surveillance systems [55, 58] indicating that the sample was repre-
sentative of the UK cancer population.
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The authors would urge caution in interpreting and generalising the findings of this study
keeping in mind the inherent methodological limitations of analysing retrospective electronic
data such as completeness, accuracy etc. We would also reiterate that our results would only
apply to cases that had symptomatic presentation before the date of diagnosis, hence some pa-
tients with emergency admissions who had missing symptom information in their records
would have been excluded, though they might have had shorter diagnostic intervals. Similarly,
screen- or incidentally-detected cancer patients would have been excluded as well. These arte-
facts would limit the generalisability of the findings. We also acknowledge that clinical hetero-
geneity within certain cancer groups in our study (e.g. leukaemia, head and neck), may also
limit the generalisability of our findings.
Implications
Interventions aimed at reducing cancer diagnostic intervals should be tailored to address in-
equalities in certain age and/or gender groups. This study has identified specific cancer sites
where such action would be of benefit. We have also provided a baseline against which future
intervention effects as well as evaluation outcomes can be assessed. More work is needed to un-
derstand the complex interaction between age, gender and types of symptoms and diagnostic
intervals, their effects on stage at diagnosis, and the types of interventions needed to address
the inequalities.
Conclusions
Diagnostic interval has been shown to vary with age, gender and NICE status across 15 differ-
ent cancers. For some, there appear to be little age and/or gender differences. However, increas-
ing age for bladder, colorectal, kidney, leukaemia, and lung cancers; female gender for bladder,
colorectal, gastric, head and neck, lung, and lymphoma cancers; and non-NICE symptoms for
10 of the 15 cancers analysed in this study were associated with longer diagnostic intervals.
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